<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293720</url>
  </required_header>
  <id_info>
    <org_study_id>09-1E</org_study_id>
    <nct_id>NCT02293720</nct_id>
  </id_info>
  <brief_title>An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System</brief_title>
  <acronym>OLE</acronym>
  <official_title>An Open-Label Extension to Protocol 09-1, Multi-Center, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the
      EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from
      study #09-1 who are not treatment failures and have completed 12 months of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label extension study for subjects who participated in the control arm of
      study #09-1 (A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the
      EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately
      Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents) who are not treatment
      failures and completed 12 months of the study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This was the cross over study for 09-1 which was terminated early
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in HbA1c value from baseline to 12 months</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes in HbA1c from baseline to 12 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the incidence of device related serious adverse events requiring an early removal</measure>
    <time_frame>52 weeks</time_frame>
    <description>Demonstrated to be less than or equal to 15%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>EndoBarrier Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoBarrier</intervention_name>
    <description>The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.</description>
    <arm_group_label>EndoBarrier Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Control subjects from study # 09-1 who are not treatment failures and have completed
             12 months of the study

          2. Age ≥21 years and ≤ 65 years

          3. Have signed an informed consent form within 30 days of week 52 visit in study #09-1.

          4. HbA1c ≥ 7.5% and ≤ 10%

          5. Stable (s) doses (up to 2) of anti -diabetes medication(s) for a minimum of 3 months
             prior to enrollment with at least one at minimum required dose as outlined below:

               1. MET (≥1500 mg/day) OR

               2. SU (based on doses specified below) Generic Name (brand name) minimum required
                  dose

                  Glimepiride (Amaryl) 4 (mg/day) Glipizide (Glucotrol) 20 (mg/day) Glipizide
                  (Glucotrol XL) 10 (mg/day) Glyburide (Micronas, Diabeta) 10 (mg/day) Micronized
                  Glyburide (Glynase) 6 (mg/day) Chlorpropamide (Diabinese) 350 (mg/day) Tolazamide
                  (Tolinase 500 (mg/day) Tolbutamide (Orinase) 1500 (mg/day) OR

               3. DPP-4i (based on doses specified below) Generic Name (brand name) minimum
                  required dose Sitagliptin (Januvia®) 50 (mg/day) Saxagliptin (Onglyza®) 2.5
                  (mg/day) Linagliptin (Tradjenta ®) 5 (mg/day) Alogliptin (Nesina®) 12.5 (mg/day)

               4. TZD (based on doses specified below) Generic Name (brand name) minimum required
                  dose Rosiglitazone (Avandia®) 4 (mg/day) Pioglitazone (Actos®) 30 (mg/day)

          6. BMI ≥ 30 and ≤ 55

          7. Willing to comply with study requirements

          8. Documented negative pregnancy test in women of childbearing potential

          9. Women of childbearing potential not intending to become pregnant for the duration of
             their trial participation

        Exclusion Criteria

          1. Any change from the subject's previous health status from assessment for eligibility
             in pivotal trial phase (such as a new condition or major illness) that places the
             subject at undue risk by participating in the study

          2. C-peptide &lt; 1.0 ng/mL

          3. Triglyceride level &gt; 400 mg/dL

          4. Vitamin D deficiency (&lt;20ng/ml)

          5. Male subjects with serum Cr &gt;1.5 mg/dl or female subjects with Cr &gt;1.4 mg/dl

          6. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet
             count less than 100,000/microliter, or known coagulopathy

          7. Symptomatic kidney stones or gallstones within 6 months prior to baseline (within 30
             days of week 52 visit from #09-1 study)

          8. Acute pancreatitis at the time of baseline (within 30 days of week 52 visit from #09-1
             study)

          9. Diagnosis of osteoporosis or currently taking bisphosphonates or teriparatide

         10. Currently taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g. aspirin,
             ibuprofen, etc.) within 10 days of the procedure and/or there is a need or expected
             need to use during the trial 12 months post index procedure

         11. Currently taking prescription antithrombotic therapy (e.g. anticoagulant or
             antiplatelet agent) within 10 days prior to the procedure and/or there is a need or
             expected need to use during the trial 12 months post index procedure

         12. Currently taking the following medications (at the time of enrollment) and/or there is
             a need or expected need to use these medications during the trial 12 months post index
             procedure:

             Restricted Medications/Supplements Systemic corticosteroids Drugs known to affect GI
             motility (e.g. Reglan) Prescription or over-the-counter weight loss medication(s)
             Medications known to cause significant weight gain (refer to study reference manual
             (SRM) or weight loss (e.g. chemotherapeutics)

         13. Currently taking ≥ two of the following medications for type 2 diabetes; MET, SU,
             DDP-4i and TZD at baseline (within 30 days of week 52 visit from #09-1 study)

         14. Currently taking medications for type 2 diabetes other than MET, SU, DPP-4i, and TZD
             (e.g. GLP1 or insulin) at baseline (within 30 days of week 52 visit from #09-1 study)

         15. Chronic use of narcotics, opiates, or benzodiazepines and other addictive
             tranquilizers

         16. Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all
             equivalent antibiotics

         17. Active H. pylori (Note: Subjects may be eligible after undergoing 2 weeks of
             antibiotic treatment without re-screening)

         18. Residing in a location without ready access to study site medical resources

         19. Documented weight loss of &gt; 10 pounds anytime during the 3 months prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

